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Abstract
Background and Objectives: N-Acetyltransferase (NAT) 2 is an important enzyme involved in the metabolism of different
xenobiotics, including potential carcinogens, whose phenotypes were reported to be related to individual susceptibility to
colorectal cancer (CRC). However, the results remain conflicting. To assess the relationship between NAT2 phenotypes and
CRC risk, we performed this meta-analysis.
Methods: A comprehensive literature search was conducted to identify all case-control or cohort studies of NAT2 acetylator
status on the susceptibility of CRC by searching of PubMed and EMBASE, up to May 20, 2011. Crude odds ratios (ORs) with
95% confidence intervals (CIs) were used to assess the association.
Results: A total of over 40,000 subjects from 40 published literatures were identified by searching the databases. No
significantly elevated CRC risk in individuals with NAT2 slow acetylators compared with fast acetylators was found when all
studies pooled (OR=0.95, 95% CI: 0.87–1.04, I
2=52.6%). While three studies contributed to the source of heterogeneity
were removed, there was still null result observed (OR=0.96, 95% CI: 0.90–1.03, P=0.17 for heterogeneity, I
2=17.8%). In
addition, we failed to detect any associations in the stratified analyses by race, sex, source of controls, smoking status,
genotyping methods or tumor localization. No publication bias was observed in this study.
Conclusions: This meta-analysis suggests that the NAT2 phenotypes may not be associated with colorectal cancer
development.
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Introduction
Colorectal cancer (CRC) is the third most common cancer
among men and women in the U.S., and ranks third as a cause of
cancer deaths [1]. The etiology of CRC is complex and
multifactorial. Hereditary syndromes, such as familial adenoma-
tous polyposis (FAP) and hereditary nonpolyposis colorectal cancer
(HNPCC), account for less than 10% of all cases [2]. The majority
of CRC is sporadic and thought to be caused by multiple factors,
which include dietary and lifestyle habits and/or mild genetic
predisposition [3]. As many experimental work and genetic
epidemiological studies conducted, many risk factors associated
with colorectal carcinogenesis are under spot light. There is
considerable evidence in support of an association between
tobacco smoke and colorectal cancer [4]. Another well-established
risk factor for CRC is red meat and, particularly, processed meat
[5]. One of the hypothesized mechanisms to explain an increased
CRC risk with smoking and meat intake is through exposure to
carcinogenic aromatic and heterocyclic amines (such as benzidine)
[6]. The metabolic activation of both aromatic and heterocyclic
amines is catalyzed by N-acetyltransferases (NAT) 1 and/or 2 that
are coded by genes (NAT1 and NAT2) which are highly
polymorphic. The carcinogenic amines can be metabolized more
or less efficiently in individuals depending on their NAT genotypes.
The NAT2 gene, which is located on chromosome 8p21.3–23.1,
and encodes phase II xenobiotic metabolizing enzyme which plays
an essential role in the metabolism of aromatic, heterocyclic
amines and hydrazines via N-acetylation and O-acetylation [7]. It
has been demonstrated that the variant alleles in NAT2 result in
slow clearance of carcinogenic amines [8] Thus, a role for NAT2
acetylation polymorphism in individual risk to various cancers in
which carcinogens exposure play an etiologic role is biologically
plausible and has been the subject of numerous studies. The high
frequency of the NAT2 acetylation polymorphisms in human
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32425populations together with ubiquitous exposure to aromatic and
heterocyclic amines suggest that NAT2 acetylator genotypes are
important modifier of human cancer susceptibility. So far, over
sixty NAT2 genetic variants have been identified in human being,
in which NAT2*4 is the most common allele associated with rapid
acetylation and has historically been designated ‘‘wildtype’’. The
NAT2 alleles are regularly updated and listed at: http://www.
louisville.edu/medschool/pharmacology/NAT.html by an inter-
national gene nomenclature committee. Detailed information on
NAT2 alleles is also provided in a supplemental file. To date, a
number of epidemiological studies have investigated the potential
role of NAT2 polymorphisms in colorectal cancer development.
However, the results were inconsistent rather than conclusive,
probably due to the possible small effect of differential acetylator
status on CRC risk or the relatively small sample size in individual
studies. Therefore we performed a meta-analysis to get a more
precise estimate of the relationship between NAT2 phenotypes and
colorectal cancer risk.
Results
Eligible studies
A total of 186 potentially relevant articles were retrieved
through electronic databases searching that met our criteria. After
carefully reviewed the titles and abstracts, 139 articles were
excluded for not about NAT genes or on colorectal polyps or
reviews. The rest 47 relevant studies were obtained for further full
text evaluating. Seven literatures were also found by hand search
of the reference lists. After information extraction and discussing,
14 studies were further excluded (7 duplications, 4 without
sufficient data, 2 on HNPCC and 1 review paper), resulting in 40
eligible studies with 13,896 CRC cases and 18,839 controls
reporting the association between the NAT2 acetylator phenotypes
and CRC risk for this meta-analysis [9–48]. The study selection
process is outlined in Figure 1. Table S1 lists the main
characteristics of the eligible studies. Among them, 19 studies
were conducted on Caucasians, 10 on Asians and 11 on mixed
populations. Only one study by Butler et al. investigated African
population [22]. Four of the 40 studies were hospital-based but a
much larger proportion was population-based (90%), thus
representing the general population. Half of the studies were
matched at least one of the following confounding factors: age, sex,
ethnicity, smoking, or meat consumption. The classic polymerase
chain reaction-restriction fragment length polymorphism (PCR-
RFLP) assay was used in twenty studies.
Quantitative synthesis
The crude ORs were performed for slow versus rapid
acetylation genotypes. Individuals with the NAT2 slow phenotypes
were not statistically significant associated with an increased risk to
colorectal cancer compared with those carrying rapid phenotypes.
The summary OR was 0.95 (95% CI: 0.87–1.04, P=0.00 for
heterogeneity, I
2=52.6%). There was substantial heterogeneity
among these studies. Herein, we explored the source of
heterogeneity. When the three studies removed [23,25,36], the
heterogeneity dropped sharply, but the summary estimate was not
materially altered (OR=0.96, 95% CI: 0.90–1.01, P=0.17 for
heterogeneity, I
2=17.8%). Figure 2 shows the forest plot of overall
comparison between slow and rapid acetylator phenotypes.
In the subgroup analysis by ethnicity, no increased risk was
found for either Caucasians (OR=0.94, 95% CI=0.87–1.02) or
Asians (OR=0.95, 95% CI=0.80–1.03). So dose mixed popula-
Figure 1. Flow chart indicates the inclusion and exclusion of studies.
doi:10.1371/journal.pone.0032425.g001
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associated increasing risk was not detected in different source of
controls (for population based controls: OR=0.98, 95%
CI=0.89–1.07; for hospital based controls: OR=0.79, 95%
CI=0.53–1.16). When stratified by genotyping methods, gender,
smoking status and tumor site, similarly, few significant associa-
tions was found for all of these subgroup analyses. The main
results of this meta-analysis and the heterogeneity tests are shown
in Table 1.
Sensitivity analyses
In sensitivity analysis, individual study was sequentially removed
each time, and the results suggested that no individual study
obviously affected the summary OR, which indicated that our
Figure 2. Forest plots of overall association between NAT2 phenotypes and colorectal cancer risk (slow acetylation versus rapid
acetylation genotypes).
doi:10.1371/journal.pone.0032425.g002
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indicated that three separate studies by Mahid et al., Yoshida et al.
and Tiemersma et al. were the main origin of the heterogeneity.
After excluding them, heterogeneity test was below statically
significant.
Publication bias
As shown in Figure 3, the shape of the funnel plot seemed
symmetrical, suggesting the absence of publication bias. Then, the
Egger’s test was adopted to provide statistical evidence of funnel
plot symmetry. The result still did not suggest any evidence of
publication bias (P=0.89).
Discussion
This meta-analysis based on 40 studies involving over 40,000
subjects indicates that lack of sufficient evidence supporting the
notion of NAT2 phenotypes correlating with the risk of colorectal
cancer. In addition, stratified analyses according to ethnicity,
source of controls, phenotyping/genotyping methods, gender,
smoking status and tumor site also indicate that NAT2 acetylator
status is not associated with CRC predisposition based on the
currently available data. As we know, this is the largest meta-
analysis of the comprehensive assessment for the relationship
between NAT2 phenotypes and CRC risk. The previous meta-
analysis didn’t support the hypothesis that NAT2 alone is an
important risk factor for colorectal cancer and suggests that NAT2
rapid acetylation status has no specific effect on the risk of
developing colorectal cancer [49]. Though there are some limits
containing in the meta-analysis (such as misclassification in case
group.), the conclusion is in consistent with ours.
Studies by meta-analysis have shown that NAT2 genetic
polymorphisms are associated with some malignancies. Reports
by Simon Sanderson et al. supported the evidence that a
contribution of NAT2 slow acetylation status alone to bladder
carcinogenesis and provided support for a NAT2-smoking
interaction [50]. However, results from other meta-analyses on
breast, lung and stomach carcinogenesis suggested that there is no
overall association between the NAT2 slow or rapid acetylation
phenotype [51–53]. The role of NAT2 genetic polymorphisms in
the development of CRC may be modified by confounding factors.
Processed meat and smoking interact with N-acetyltransferases
efficiency on colorectal cancer risk have received a great deal of
attention in some studies. Moreover, an enhanced association
between smoking and colorectal cancer risk in subjects with the
NAT2 rapid genotype was detected and supported a role for NAT2
and tobacco smoke heterocyclic amines in the etiology of
colorectal cancer [19]. Meanwhile, detoxification of polycyclic
aromatic hydrocarbons may involve many other genes that might
influence the action of NAT2 examined. Other genes, including
other CYPs, GSTs, NAT1, and the aromatic hydrocarbon receptor
gene, which positively regulates inducible expression of aromatic
hydrocarbon hydroxylase, may further define genetic susceptibility
to the exposure of carcinogenic amines [32]. Even if heterocyclic
Table 1. Main results of overall and subgroups in the meta-analysis.
Overall and subgroups analyses No. of studies OR 95% CI Heterogeneity
P value I
2 (%)
Total 42 0.95 0.87–1.04 ,0.001 52.6
Total* 39 0.96 0.90–1.01 0.17 17.8
Ethnicity
Asian 9 0.95 0.80–1.03 0.55 0.00
Caucasian 19 0.94 0.87–1.02 0.04 39.6
Mixed 10 0.97 0.89–1.07 0.44 0.20
Source of controls
Population based 37 0.98 0.89–1.07 0.001 52.8
Hospital based 4 0.79 0.53–1.16 0.44 0.00
Genotyping methods
PCR-RFLP 20 0.98 0.87–1.10 0.04 39.8
PCR-RFLP/(AS)-PCR 3 0.81 0.57–1.16 0.39 0.00
F-based melting curve 2 0.87 0.70–1.09 0.78 0.00
TaqMan 4 0.72 0.46–1.12 ,0.001 89.0
Gender
Male 6 1.16 0.95–1.42 0.94 0.00
Female 6 1.03 0.74–1.42 0.04 57.1
Smoking status
Never smoke 5 0.93 0.66–1.32 0.01 69.8
Ever smoke 6 0.89 0.69–1.15 0.07 51.9
Tumor site
Colon cancer 3 0.91 0.80–1.05 0.86 0.00
Rectal cancer 3 1.07 0.92–1.24 0.77 0.00
*Three studies excluded for exploring the source of heterogeneity. [23], [25], [36], confidence interval, CI.
doi:10.1371/journal.pone.0032425.t001
NAT2 Phenotypes and Colorectal Carcinoma Risk
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32425amines are a causal factor for CRC, other enzymes are involved in
the activation and detoxification of such compounds, thus
accounting only for NAT2 provides only a partial picture of the
whole pathway.
Since multiple mechanisms for reductions in NAT2 activity are
associated with various combinations of variants that make up
NAT2 alleles, the ability to distinguish among multiple acetylator
phenotypes is complex and a function of the sensitivity and
specificity of the genotyping method. Furthermore, phenotypes are
influenced by a number of factors including diet, disease, and drug
therapy. Depending upon the probe drug and analytical method
used, acetylation phenotypes often exhibit overlap due to
numerous genetic and/or environmental factors, including the
large number and diversity of NAT2 genotypes present in human
populations (reviewed in [54]). Thus, the nondifferential misclas-
sification would likely bias the results to the null.
Some limitations of this meta-analysis should be mentioned.
First of all, ethnic differences in NAT2 allelic frequencies are quite
striking and should be cautious when interpreting the results. e.g.
the prevalence of NAT2 slow acetylators in European whites is
approximately 56% and about 11% among Asians [55]. The
difference can lead to bias in choosing control groups and masking
the effect of NAT2 acetylator in molecular epidemiologic studies.
Secondly, there was significant heterogeneity between the studies.
Figure 3. Funnel plots of Begg’s and Egger’s were used to detect publication bias on overall estimate. No significant publication bias
was found. Each point represents an individual study for the indicated association.
doi:10.1371/journal.pone.0032425.g003
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could possibly explain the origin of observed heterogeneity. The
cause of the heterogeneity may be partially explained by the ethnic
diversity (two studies select mixed ethnic control groups [25,36]).
However, the systemic result was not affected after the exclusion.
Thirdly, the sample size is still relatively small for some stratified
analyses, might fail to detect small effect of NAT2 phenotypes on
colorectal cancer risk in specific stratification. Although no
correlation between NAT2 phenotypes and CRC risk was found
pooling the data from 6 studies which stratified smoking status, a
precise measurement of exposure to carcinogens may be helpful to
understand the biological mechanisms when genes involved in
metabolic pathways are assessed. Lastly, the results were based on
unadjusted estimates, while a more precise analysis should be
conducted if all individual raw data were available, which would
allow for an adjustment estimate.
In spite of these limitations, this meta-analysis had several
strengths. First, it is the largest number of cases and controls were
pooled to date, which substantially increased the statistical power
of the analysis. Second, no publication biases were detected,
indicating that summary results may be unbiased. Third, in the
sensitivity analysis, no individual study affected the pooled OR
which indicated that our results were statistically robust and
trustworthy.
In conclusion, the meta-analysis failed to detect a significant
association between NAT2 phenotypes and predisposition to
colorectal cancer. However, CRC is a multifactor and multipro-
cessing disease that resulted from complex interactions between
gene–gene and gene–environment. Therefore, further large and
well-designed epidemiological studies with considering potential
interactions and more precise measurement of exposure to
carcinogens are needed.
Methods
Identification and eligibility of relevant studies
We searched for relevant papers published before May 20, 2011
using the electronic PubMed and EMBASE databases with the
following terms and their combinations: ‘NAT2’o r‘ N-acetyltrans-
ferase 2’, ‘colon cancer’, ‘rectal cancer’, ‘colorectal cancer’ and
‘polymorphism’ or ‘variant’. No language restriction was imposed.
References of the retrieved articles were also reviewed for
additional studies. We included all the case–control and cohort
studies that reported the association between NAT2 polymor-
phisms and colorectal cancer risk with sufficient data for
estimating an odds ratio (OR) and their 95% confidence intervals
(CIs). Abstracts, unpublished data were not considered. Investiga-
tions in subjects with family cancer risks or cancer-prone
disposition were excluded. Besides, when the same study
population was included by more than one article, we selected
the study that included the largest number of individuals.
Data extraction
We extracted the following information from each study: first
author’s surname, year of publication, country of origin, ethnicity,
phenotyping/genotyping information, source of control groups
(population-based, hospital-based or mixed controls), matching
criteria and number of different genotypes in all subjects. The
ethnicity of studies was categorized as Asians, Caucasians, African
or Mixed. We defined carriers with at least one of the high-activity
alleles as rapid acetylators, in accordance with the definition in
most studies, whereas individuals carrying two low-activity alleles
were considered as slow acetylators. All the data were extracted
separately by two authors (Zhang LQ and Wang J), and the
disagreement was solved by discussing.
Statistical analysis
The meta-analysis was performed to estimate the risk of
colorectal cancer associated with NAT2 slow/rapid acetylation
polymorphisms. Crude ORs with 95% CIs were calculated using
raw data, according to the method of Woolf B. [56]. In addition to
the comparison among overall subjects, we also performed
stratified analyses by ethnicity, genotyping method, source of
controls, gender, tumor localization and smoking status. We
investigated the between-study heterogeneity by using the
Cochran’s Q-test and estimating I
2, respectively. And the
heterogeneity was considered significant, if P,0.10 for Q-test
[57]. A p-value .0.10 for the Q-test indicated a lack of
heterogeneity across the studies, and a fixed-effect model (the
Mantel–Haenszel method) [58] was used, otherwise a random-
effect model (the DerSimonian and Laird method) [59] was used.
One-way sensitivity analysis was performed to assess the stability of
the results, namely, a single study in the meta-analysis was deleted
each time to reflect the influence of the individual data set to the
pooled OR. Funnel plots and the Egger’s test were used to
examine the influence of publication bias (linear regression
analysis) [60]. All analyses were conducted using Stata software
(version 11.0; Stata Corp LP, College Station, TX). All the p-
values were two-sided.
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